GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zivo Bioscience Inc (OTCPK:ZIVO) » Definitions » Asset Turnover

Zivo Bioscience (Zivo Bioscience) Asset Turnover : 0.05 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zivo Bioscience Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Zivo Bioscience's Revenue for the three months ended in Mar. 2024 was $0.04 Mil. Zivo Bioscience's Total Assets for the quarter that ended in Mar. 2024 was $0.69 Mil. Therefore, Zivo Bioscience's Asset Turnover for the quarter that ended in Mar. 2024 was 0.05.

Asset Turnover is linked to ROE % through Du Pont Formula. Zivo Bioscience's annualized ROE % for the quarter that ended in Mar. 2024 was 228.47%. It is also linked to ROA % through Du Pont Formula. Zivo Bioscience's annualized ROA % for the quarter that ended in Mar. 2024 was -745.19%.


Zivo Bioscience Asset Turnover Historical Data

The historical data trend for Zivo Bioscience's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zivo Bioscience Asset Turnover Chart

Zivo Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.07 - - 0.02

Zivo Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.01 0.01 0.05

Competitive Comparison of Zivo Bioscience's Asset Turnover

For the Biotechnology subindustry, Zivo Bioscience's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zivo Bioscience's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zivo Bioscience's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Zivo Bioscience's Asset Turnover falls into.



Zivo Bioscience Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Zivo Bioscience's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.028/( (2.123+0.556)/ 2 )
=0.028/1.3395
=0.02

Zivo Bioscience's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0.036/( (0.556+0.816)/ 2 )
=0.036/0.686
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Zivo Bioscience  (OTCPK:ZIVO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Zivo Bioscience's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-5.112/-2.2375
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-5.112 / 0.144)*(0.144 / 0.686)*(0.686/ -2.2375)
=Net Margin %*Asset Turnover*Equity Multiplier
=-3550 %*0.2099*-0.3066
=ROA %*Equity Multiplier
=-745.19 %*-0.3066
=228.47 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Zivo Bioscience's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-5.112/0.686
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-5.112 / 0.144)*(0.144 / 0.686)
=Net Margin %*Asset Turnover
=-3550 %*0.2099
=-745.19 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Zivo Bioscience Asset Turnover Related Terms

Thank you for viewing the detailed overview of Zivo Bioscience's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Zivo Bioscience (Zivo Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
21 East Long Lake Road, Suite 100, Bloomfield Hills, MI, USA, 48304
Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's pipeline candidates are; Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Human Food Ingredients, and Skin Health.
Executives
Alison A Cornell director 210 CARNEGIE CENTER, PRINCETON NJ 08540
Christopher D. Maggiore officer: CHIEF FINANCIAL OFFICER 4788 NOBLES POND DR. NW, CANTON OH 44718
Nola E Masterson director 768 WEST CALIFORNIA WAY, WOODSIDE CA 94062
John Bernard Payne director 9900 NE 114TH CIRCLE, VANCOUVER WA 98662
Strome Mezzanine Fund, Lp 10 percent owner 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Keith Marchiando officer: Chief Financial Officer C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304
Mark E Strome 10 percent owner 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Strome Alpha Fund L P 10 percent owner 100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401
Strome Investment Management Lp 10 percent owner 100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401
Strome Group, Inc. 10 percent owner 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Hep Investments Llc 10 percent owner 2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320
Rondeau Robert O Jr director 70 WEST LONG LAKE RD, STE 119, TROY MI 48098
Thomas Kevin Cox director 470 MICHGAMME LANE, LAKE FOREST IL 60045
Andrew A Dahl officer: President, CEO 7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302
Brian W Young other: See remarks below. 1800 NW CORPORATE BLVD, BOCA RATON FL 33431